medigraphic.com
Instituto Nacional de Salud Pública

2018, Number 6

<< Back Next >>

salud publica mex 2018; 60 (6)

HPV vaccine acceptance is high among adults in Mexico, particularly in people living with HIV

Portillo-Romero AJ, León-Maldonado L, Allen-Leigh B, Brown B, Magis C, García-Fuentes NB, Salmerón J, Hurtado E, Torres-Ibarra L, Rivera-Paredez B, Hernández-López R, Yunes-Díaz E, Lazcano-Ponce E

Language: English
References: 59
Page: 658-665
PDF size: 309.58 Kb.


ABSTRACT

Materials and methods. A total of 1 329 men and women, with and without HIV, participated in one of three intervention studies, offering HPV vaccination, carried out in the states of Morelos, Tlaxcala and Mexico City; either the bivalent (Morelos n=103, Tlaxcala n=127) or quadrivalent HPV-vaccine (Mexico City n=1 099) was offered. Results. HPV vaccine was accepted by 80.3% of participants; acceptance was higher in people living with HIV than those without (84.4 vs. 78%, p=0.004). Women had greater HPV infection knowledge (p‹0.0001) than men and slightly higher (p=0.4) vaccine acceptance. The main reason for vaccine non-acceptance among HIV-positive participants was their doctor recommended they not get vaccinated. Conclusion. Acceptance of HPV-vaccine was high in men and women re- gardless of HIV status. Even higher rates of acceptability may be achieved by educating healthcare providers to recommend HPV vaccine to their patients.


REFERENCES

  1. Burchell AN, Winer RL, de Sanjosé S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24(suppl 3):S3/52-61. https://doi.org/10.1016/j.vaccine.2006.05.031

  2. Giuliano AR, Lazcano-Ponce E, Villa LL, Flores R, Salmeron J, Lee JH, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev. 2008;17(8):2036-43. https://doi.org/10.1158/1055-9965.EPI-08-0151

  3. Barroso LF 2nd. The role of Human Papilloma Virus (HPV) vaccination in the prevention of anal cancer in individuals with Human Immunodeficiency Virus-1 (HIV-1) infection. Ther Adv Vaccines. 2013;1(2):81-92. https://doi.org/10.1177/2051013613496946

  4. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124(7):1626-36. https://doi.org/10.1002/ijc.24116

  5. Gomez-Dantés H, Lamadrid-Figueroa H, Cahuana-Hurtado L, Silverman- Retana O, Montero P, González-Robledo MC, et al. The burden of cancer in Mexico, 1990-2013. Salud Publica Mex. 2016;58(2):118-31. https://doi. org/10.21149/spm.v58i2.7780

  6. Bray F, Piñeros M. Cancer patterns, trends and projections in Latin America and the Caribbean: A global context. Salud Publica Mex. 2016;58(2):104-17. https://doi.org/10.21149/spm.v58i2.7779

  7. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609-16. https://doi.org/10.1016/S2214- 109X(16)30143-7

  8. Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS. 2009;4(1):52-6. https://doi.org/10.1097/ COH.0b013e32831a7246

  9. Combes JD, Clifford GM, Egger M, Cavassini M, Hirsch HH, Hauser C, et al. Human papillomavirus antibody response following HAART initiation among MSM. AIDS. 2017;31(4):561-9. https://doi.org/10.1097/ QAD.0000000000001354

  10. Loverro G, Di Naro E, Caringella AM, De Robertis AL, Loconsole D, Chironna M. Prevalence of human papillomavirus infection in a clinic sample of transsexuals in Italy. Sex Transm Infect. 2016;92(1):67-9. https:// doi.org/10.1136/sextrans-2014-051987

  11. Garland SM, Subasinghe AK, Jayasinghe YL, Wark JD, Moscicki AB, Singer A, et al. HPV vaccination for victims of childhood sexual abuse. Lancet. 2015;386(10007):1919-20. https://doi.org/10.1016/S0140-6736(15)00757-6

  12. Tejada RA, Vargas KG, Benites-Zapata V, Mezones-Holguín E, Bolaños- Díaz R, Hernandez AV. Human papillomavirus vaccine efficacy in the prevention of anogenital warts: systematic review and meta-analysis. Salud Publica Mex. 2017;59(1):84-94 . https://doi.org/10.7910/DVN/HCMDYJ

  13. Torres-Ibarra L, Lazcano-Ponce E, Franco EL, Cuzick J, Hernández-Ávila M, Lorincz A, et al. Triage strategies in cervical cancer detection in Mexico: Methods of the FRIDA study. Salud Publica Mex. 2016;58(2):197-210. https://doi.org/10.21149/spm.v58i2.7789

  14. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year endof- study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89-99. https://doi.org/10.1016/S1470-2045(11)70286-8

  15. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-27. https://doi.org/10.1056/NEJMoa061741

  16. Kjaer SK, Sigurdsson K, Iversen OE, Hernández-Avila M, Wheeler CM, Perez G, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila). 2009;2(10):868-78. https://doi.org/10.1158/1940-6207.CAPR-09-0031

  17. Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males- -Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(50):1705-8.

  18. Schwarz TF, Galaj A, Spaczynski M, Wysocki J, Kaufmann AM, Poncelet S, et al. Ten-year immune persistence and safety of the HPV-16/18 AS04- adjuvanted vaccine in females vaccinated at 15-55 years of age. Cancer Med. 2017;6(11):2723-31. https://doi.org/10.1002/cam4.1155

  19. Hidalgo-Tenorio C, Ramírez-Taboada J, Gil-Anguita C, Esquivias J, Omar-Mohamed-Balgahata M, SamPedro A, et al. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM). AIDS Res Ther. 2017;14:34. https://doi.org/10.1186/s12981-017-0160-0

  20. Zhu FC, Hu SY, Hong Y, Hu YM, Zhang X, Zhang YJ, et al. Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial. Cancer Med. 2017;6(1):12-25. https://doi.org/10.1002/ cam4.869

  21. Money DM, Moses E, Blitz S, Vandriel SM, Lipsky N, Walmsley SL, et al. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. Vaccine. 2016;34(40):4799-806. https://doi.org/10.1016/j. vaccine.2016.08.016

  22. Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016;16(10):1154-68. https:// doi.org/10.1016/S1473-3099(16)30120-7

  23. Palefsky JM, Gillison ML, Strickler HD. Chapter 16. HPV vaccines in immunocompromised women and men. Vaccine. 2006;24(suppl 3):S140-6. https://doi.org/10.1016/j.vaccine.2006.05.120

  24. https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ ucm094042.htm

  25. Mazza D, Petrovic K, Grech C, Harris N. HPV vaccination in women aged 27 to 45 years: what do general practitioners think? BMC Womens Health. 2014;14:91. https://doi.org/10.1186/1472-6874-14-91

  26. Donders GG, Gabrovska M, Bellen G, Van KJ, Van Den BT, Riphagen I, et al. Knowledge of cervix cancer, human papilloma virus (HPV) and HPV vaccination at the moment of introduction of the vaccine in women in Belgium. Arch Gynecol Obstet. 2008; 277:291-8. https://doi.org/10.1007/ s00404-007-0487-1

  27. Gerend MA, Barley J. Human papillomavirus vaccine acceptability among young adult men. Sex Transm Dis. 2009;36:58-62. https://doi. org/10.1097/OLQ.0b013e31818606fc

  28. Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet Gynecol. 2008;111:1103-10. https://doi.org/10.1097/AOG.0b013e31817051fa

  29. Marshall H, Ryan P, Roberton D, Baghurst P. A cross-sectional survey to assess community attitudes to introduction of Human Papillomavirus vaccine. Aust NZJ Public Health. 2007;31:325-42. https://doi.org/10.1111/ j.1467-842X.2007.00054.x

  30. Woodhall SC, Lehtinen M, Verho T, Huhtala H, Hokkanen M, Kosunen E. Anticipated acceptance of HPV vaccination at the baseline of implementation: A survey of parental and adolescent knowledge and attitudes in Finland. J Adolesc Health. 2007;40:466-9. https://doi.org/10.1016/j. jadohealth.2007.01.005

  31. Friedman AL, Shepeard H. Exploring the knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV: findings from CDC focus group research and implications for practice. Health Educ Behav. 2007;34(3):471-85. https://doi. org/10.1177/1090198106292022

  32. Sauvageau C, Duval B, Gilca V, Lavoie F, Ouakki M. Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health. 2007;7:304. https://doi. org/10.1186/1471-2458-7-304

  33. Tian T, Wang D, Papamichael C, Yan Z, Guoyao S, Zhanlin Z, et al. HPV vaccination acceptability among men who have sex with men in Urumqi, China. Hum Vaccin Immunother. 2018. https://doi.org/10.1080/21645515. 2018.1520591

  34. Poole DN, Tracy JK, Levitz L, Rochas M, Sangare K, Yekta S, et al. A cross-sectional study to assess HPV knowledge and HPV vaccine acceptability in Mali. PLoS One. 2013;8(2):e56402. https://doi.org/10.1371/journal. pone.0056402

  35. Godoy-Verdugo MK, Zonana-Nacach A, Anzaldo-Campos MC. Aceptación de la vacuna contra el virus del papiloma humano por parte de madres de hijas entre 9 y 13 años de edad. Ginecol Obstet Mex. 2013;81(11):645-51.

  36. Gamaoun R. Knowledge, awareness and acceptability of anti-HPV vaccine in the Arab states of the Middle East and North Africa Region: a systematic review. East Mediterr Health J. 2018;24(6):538-48. https://doi. org/10.26719/2018.24.6.538

  37. Cunningham MS, Davison C, Aronson KJ. HPV vaccine acceptability in Africa: a systematic review. Prev Med. 2014;69:274-9. https://doi. org/10.1016/j.ypmed.2014.08.035

  38. Degarege A, Krupp K, Fennie K, Srinivas V, Li T, Stephens DP, et al. Human Papillomavirus Vaccine acceptability among parents of adolescent girls in a rural area, Mysore, India. J Pediatr Adolesc Gynecol. 2018. 31(6):583- 91. https://doi.org/ 10.1016/j.jpag.2018.07.008

  39. Vermandere H, van Stam MA, Naanyu V, Michielsen K, Degomme O, Oort F. Uptake of the human papillomavirus vaccine in Kenya: testing the health belief model through pathway modeling on cohort data. Global Health. 2016;12(1):72. https://doi.org/10.1186/s12992-016-0211-7

  40. Kabakama S, Gallagher KE, Howard N, Mounier-Jack S, Burchett HE, Griffiths UK, et al. Social mobilization, consent and acceptability: a review of human papillomavirus vaccination procedures in low and middle-income countries. BMC Public Health. 2016;16(1):834. https://doi.org/10.1186/ s12889-016-3517-8

  41. Lazcano-Ponce E, Rivera L, Arillo-Santillán E, Salmerón J, Hernández- Avila M, Muñoz N. Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch Med Res. 2001;32(3):243-7. https://doi.org/10.1016/S0188- 4409(01)00277-6

  42. Perez S, Zimet GD, Tatar O, Stupiansky NW, Fisher WA, Rosberger Z. Human Papillomavirus Vaccines: Successes and Future Challenges. Drugs. 2018;78(14):1385-96. https://doi.org/10.1007/s40265-018-0975-6

  43. Fenton AT, Eun TJ, Clark JA, Perkins RB. Indicated or elective? The association of providers’ words with HPV vaccine receipt. Hum Vaccin Immunother. 2018;14(10):2503-9. https://doi.org/10.1080/21645515.201 8.1480237

  44. Rosenthal SL, Weiss TW, Zimet GD, Ma L, Good MB, Vichnin MD. Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician’s recommendation. Vaccine. 2011;29(5):890-5. https://doi. org/10.1016/j.vaccine.2009.12.063

  45. Attia AC, Wolf J, Núñez AE. On surmounting the barriers to HPV vaccination: we can do better. Ann Med. 2018;50(3):209-25. https://doi.org/ 10.1080/07853890.2018.1426875

  46. Sadlier C, Lynam A, O’Dea S, Delamere S, Quinlan M, Clarke S, et al. HPV vaccine acceptability in HIV-infected and HIV negative men who have sex with men (MSM) in Ireland. Hum Vaccin Immunother. 2016;12(6):1536-41. https://doi.org/10.1080/21645515.2016.1151588

  47. Wheldon CW, Daley EM, Walsh-Buhi ER, Baldwin JA, Nyitray AG, Giuliano AR. An integrative theoretical framework for HPV Vaccine promotion among male sexual minorities. Am J Mens Health. 2018;12(5):1409-20. https://doi.org/10.1177/1557988316652937

  48. Wadhera P, Evans JL, Stein E, Gandhi M, Couture MC, Sansothy N, et al. HPV knowledge, vaccine acceptance, and vaccine series completion among female entertainment and sex workers in Phnom Penh, Cambodia: the Young Women’s Health Study. Int J STD AIDS. 2015;26(12):893-902. https://doi.org/10.1177/0956462414563626

  49. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infec Dis. 2002;35(9):1127-34. https:// doi.org/10.1086/344057

  50. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. New Engl J Med. 1997;337(19):1343-9. https://doi. org/10.1056/NEJM199711063371903

  51. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1-30.

  52. Gilca V, Salmerón-Castro J, Sauvageau C, Ogilvie G, Landry M, Naus M, Lazcano-Ponce E. Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact. Vaccine. 2018;36(32 Pt A):4800-5. https://doi.org/10.1016/j.vaccine.2018.02.004

  53. Wallace L, Kapirir L. How are new vaccines prioritized in lowincome countries? A case study of human papilloma virus vaccine and pneumococcal conjugate vaccine in Uganda. Int J Health Policy Manag. 2017;6(12):707-20. https://doi.org/10.15171/ijhpm.2017.37

  54. Patel H, Wilson E, Vizzotti C, Parston G, Prestt J, Darzi A. Argentina’s successful implementation of a national human papillomavirus vaccination program. Health Aff (Millwood). 2016;35(2):301-8. https://doi.org/10.1377/ hlthaff.2015.1416

  55. Wheldon CW, Sutton SK, Fontenot HB, Quinn GP, Giuliano AR, Vadaparampil ST. Physician communication practices as a barrier to risk-based HPV Vaccine uptake among men who have sex with men. J Cancer Educ. 2018;33(5):1126-31. https://doi.org/10.1007/s13187-017-1223-6

  56. Crann SE, Barata PC, Mitchell R, Mawhinney L, Thistle P, Chirenje ZM, Stewart DE. Healthcare providers’ perspectives on the acceptability and uptake of HPV vaccines in Zimbabwe. J Psychosom Obstet Gynaecol. 2016;37(4):147-55. https://doi.org/10.1080/0167482X.2016.1199544

  57. Garbutt JM, Dodd S, Walling E, Lee AA, Kulka K, Lobb R. Barriers and facilitators to HPV vaccination in primary care practices: a mixed methods study using the Consolidated Framework for Implementation Research. BMC Fam Pract. 2018;19(1):53. https://doi.org/ 10.1186/s12875-018-0750-5

  58. Malo TL, Hall ME, Brewer NT, Lathren CR, Gilkey MB. Why is announcement training more effective than conversation training for introducing HPV vaccination? A theory-based investigation. Implement Sci. 2018;13(1):57. https://doi.org/10.1186/s13012-018-0743-8

  59. Wigfall LT, Bynum SA, Brandt HM, Hébert JR. HPV vaccine awareness and knowledge among women living with HIV. J Cancer Educ. 2016;31(1):187-90. https://doi.org/10.1007/s13187-015-0943-8




2020     |     www.medigraphic.com